170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

For years, disease diagnosis and treatment have focused on a few biomarkers, overlooking thousands of vital biological signals. Despite biotech advances, most therapies are still based on limited data, missing countless breakthroughs.Multiomics changes that. By analyzing tens of thousands of proteins, metabolites, and lipids, it reveals hidden insights, paving the way for smarter, faster, and more effective medical discoveries.In this must-listen episode, David Brühlmann welcomes Mo Jain, founder and CSO of Sapient, a pioneering force in bringing multiomic platforms out of academia and into the heart of drug development. A physician-scientist by training and a visionary entrepreneur by choice, Mo’s journey spans decades at the cutting edge of analytical technologies, culminating in the creation of ultra-high-throughput systems that analyze up to 20,000 biomarkers in a single run for real-world impact.Here are three reasons why this episode needs to be on your playlist:Multiomics at Scale: Mo shares how his team at Sapient turbocharged mass spectrometry, enabling simultaneous measurement of thousands of molecules, transforming routine diagnostics and making previously unimaginable insights accessible to scientists everywhere.Turning Data into Action: Generating vast data is only half the battle. Mo explains how Sapient developed advanced biocomputational teams and frameworks to extract actionable answers, guiding drug developers to faster, smarter decisions and helping avoid the pitfalls that cripple so many omics projects.The Future Is Personalized and Sooner Than You Think: From dramatically earlier disease detection to truly personalized therapies, Mo paints an optimistic picture of a coming era where AI, multiomics, and new therapeutic modalities rapidly accelerate both discovery and delivery, reshaping how biotech companies tackle even the toughest diseases.Ready to break out of the 20-biomarker rut and see what 20,000 data points can reveal? Tune in to discover how you can harness multiomics in your own research and hear Mo’s advice for scientists and entrepreneurs venturing beyond the bench.Connect with Mo Jain:LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895baWebsite: www.sapient.bioCompany LinkedIn Page: https://www.linkedin.com/company/sapientbioNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show